Early-stage cancer drug maker Surface Oncology (NASDAQ: SURF) has hired an investment bank to explore a potential sale after receiving ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE